A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

@article{Ang2011ARP,
  title={A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).},
  author={K. Kian Ang and Qiang Zhang and David I. Rosenthal and Phuc Felix Nguyen-Tan and Eric J Sherman and Randal S. Weber and J. M. Galvin and David Schwartz and A El-naggar and Maura L. Gillison and Richard C. K. Jordan and Marcie List and Andre A. Konski and W. L. Thorstad and Andy M. Trotti and J J Beitler and Adam Seth Garden and William J. Spanos and Sue S Yom and Rita Susan Axelrod},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={5500}
}
5500 Background: The concurrent use of cisplatin (CDDP) or cetuximab (CET) with radiation (RT) has been shown to improve survival of patients with stage III-IV HNC. Since CET enhances the response of metastatic HNC to platinum-containing regimens and survival, the RTOG launched a phase III trial to test the hypothesis that adding CET to the RT-CDDP platform for frontline therapy of stage III-IV HNC improves progression free survival. METHODS Patients with stage III-IV carcinoma of the… CONTINUE READING